Bright Minds Biosciences (DRUG) to Post Quarterly Earnings on Thursday

Key Points

• Bright Minds Biosciences is expected to report Q3 2026 results before the market opens on August 13, 2026. Analysts forecast a quarterly loss of $1.2831 per share; the company previously reported a $0.80 per-share loss, beating estimates.
• DRUG shares opened at $80, with a 12-month range of $33.96 to $123.75 and a market capitalization of approximately $778.4 million. Hedge funds and other institutions own 40.52% of the stock.
• Analysts maintain a broadly positive view, with a consensus “Buy” rating and an average price target of $143.83. Bright Minds is developing oral therapies for mental health and neurodegenerative disorders, including lead candidate BMB-101.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) is expected to be releasing its Q3 2026 results before the market opens on Thursday, August 13th. Analysts expect Bright Minds Biosciences to post earnings of ($1.2831) per share for the quarter. Investors can check the company's upcoming Q3 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.80) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.06. On average, analysts expect Bright Minds Biosciences to post $-5 EPS for the current fiscal year and $-7 EPS for the next fiscal year.

Bright Minds Biosciences Price Performance

Shares of Bright Minds Biosciences stock opened at $80.00 on Thursday. The business has a 50 day simple moving average of $70.67 and a two-hundred day simple moving average of $77.48. Bright Minds Biosciences has a 12 month low of $33.96 and a 12 month high of $123.75. The stock has a market capitalization of $778.40 million, a P/E ratio of -32.79 and a beta of -5.27.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Virtu Financial LLC purchased a new stake in Bright Minds Biosciences in the fourth quarter valued at $226,000. Invesco Ltd. purchased a new position in Bright Minds Biosciences during the fourth quarter worth about $328,000. Ikarian Capital LLC increased its position in shares of Bright Minds Biosciences by 933.1% during the fourth quarter. Ikarian Capital LLC now owns 159,421 shares of the company's stock valued at $12,441,000 after acquiring an additional 143,990 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of Bright Minds Biosciences in the 4th quarter valued at approximately $1,068,000. Finally, Millennium Management LLC lifted its holdings in shares of Bright Minds Biosciences by 153.6% in the 4th quarter. Millennium Management LLC now owns 194,437 shares of the company's stock worth $15,174,000 after acquiring an additional 117,756 shares during the last quarter. 40.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DRUG shares. Jefferies Financial Group assumed coverage on shares of Bright Minds Biosciences in a research report on Monday, April 13th. They issued a "buy" rating and a $145.00 target price for the company. HC Wainwright restated a "buy" rating and set a $145.00 price target on shares of Bright Minds Biosciences in a research report on Monday, June 1st. Wall Street Zen raised shares of Bright Minds Biosciences from a "strong sell" rating to a "sell" rating in a research note on Saturday, July 4th. Piper Sandler reissued an "overweight" rating and issued a $220.00 target price (up from $190.00) on shares of Bright Minds Biosciences in a research note on Wednesday, May 20th. Finally, Zacks Research upgraded Bright Minds Biosciences from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 21st. One research analyst has rated the stock with a Strong Buy rating and six have given a Buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $143.83.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source